Rock Point Advisors LLC Acquires 19,940 Shares of LivaNova PLC $LIVN

Rock Point Advisors LLC raised its holdings in LivaNova PLC (NASDAQ:LIVN) by 34.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 78,475 shares of the company’s stock after buying an additional 19,940 shares during the quarter. Rock Point Advisors LLC owned about 0.14% of LivaNova worth $4,829,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. Arizona State Retirement System grew its position in shares of LivaNova by 1.7% in the 3rd quarter. Arizona State Retirement System now owns 16,129 shares of the company’s stock worth $845,000 after buying an additional 274 shares during the last quarter. Bayforest Capital Ltd grew its position in shares of LivaNova by 44.8% in the 3rd quarter. Bayforest Capital Ltd now owns 918 shares of the company’s stock worth $48,000 after buying an additional 284 shares during the last quarter. UMB Bank n.a. grew its position in shares of LivaNova by 63.0% in the 3rd quarter. UMB Bank n.a. now owns 792 shares of the company’s stock worth $41,000 after buying an additional 306 shares during the last quarter. California State Teachers Retirement System grew its position in shares of LivaNova by 0.9% in the 2nd quarter. California State Teachers Retirement System now owns 50,202 shares of the company’s stock worth $2,260,000 after buying an additional 458 shares during the last quarter. Finally, PNC Financial Services Group Inc. grew its position in shares of LivaNova by 31.9% in the 3rd quarter. PNC Financial Services Group Inc. now owns 1,901 shares of the company’s stock worth $100,000 after buying an additional 460 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on LIVN shares. Mizuho lifted their price objective on LivaNova from $85.00 to $90.00 and gave the stock an “outperform” rating in a research report on Thursday, May 7th. Barclays raised their target price on LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a research note on Thursday, May 7th. Stifel Nicolaus set a $80.00 target price on LivaNova in a research note on Wednesday, February 25th. Robert W. Baird lowered their target price on LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Finally, Needham & Company LLC raised their target price on LivaNova from $64.00 to $81.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Seven equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, LivaNova currently has an average rating of “Moderate Buy” and a consensus target price of $77.22.

LivaNova Trading Up 2.4%

LIVN opened at $71.75 on Wednesday. The stock has a market cap of $3.94 billion, a PE ratio of 36.79 and a beta of 0.82. The company has a quick ratio of 1.11, a current ratio of 1.33 and a debt-to-equity ratio of 0.24. The business has a 50 day moving average of $64.04 and a 200-day moving average of $62.50. LivaNova PLC has a 52 week low of $41.01 and a 52 week high of $72.78.

LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, May 6th. The company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.13. The company had revenue of $362.26 million during the quarter, compared to analysts’ expectations of $346.05 million. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The firm’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.88 EPS. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. Equities research analysts predict that LivaNova PLC will post 3.68 earnings per share for the current fiscal year.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.